MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Heron Therapeutics Inc

Затворен

СекторЗдравеопазване

2.14 -4.04

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.12

Максимум

2.22

Ключови измерители

By Trading Economics

Приходи

8.5M

3.7M

Продажби

-1.5M

41M

EPS

0.02

Марж на печалбата

8.982

Служители

122

EBITDA

13M

8.7M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+208.06% upside

Дивиденти

By Dow Jones

Следващи печалби

6.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

77M

346M

Предишно отваряне

6.18

Предишно затваряне

2.14

Настроения в новините

By Acuity

35%

65%

122 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Heron Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.04.2025 г., 23:55 ч. UTC

Горещи акции

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2.04.2025 г., 22:50 ч. UTC

Значими двигатели на пазара

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2.04.2025 г., 21:08 ч. UTC

Печалби

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2.04.2025 г., 21:00 ч. UTC

Печалби

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2.04.2025 г., 23:56 ч. UTC

Пазарно говорене

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2.04.2025 г., 23:44 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.04.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2.04.2025 г., 23:44 ч. UTC

Топ новини

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2.04.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.04.2025 г., 23:12 ч. UTC

Пазарно говорене

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2.04.2025 г., 23:10 ч. UTC

Пазарно говорене

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2.04.2025 г., 23:09 ч. UTC

Пазарно говорене

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2.04.2025 г., 23:09 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 22:57 ч. UTC

Пазарно говорене

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2.04.2025 г., 22:56 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 22:56 ч. UTC

Пазарно говорене

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2.04.2025 г., 22:43 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2.04.2025 г., 22:12 ч. UTC

Пазарно говорене

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2.04.2025 г., 21:48 ч. UTC

Топ новини

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2.04.2025 г., 21:41 ч. UTC

Пазарно говорене

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2.04.2025 г., 21:04 ч. UTC

Топ новини

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2.04.2025 г., 21:03 ч. UTC

Пазарно говорене

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2.04.2025 г., 20:53 ч. UTC

Печалби

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2.04.2025 г., 20:52 ч. UTC

Печалби

Kaiser Aluminum Changes Inventory Acctg Methodology

Сравнение с други в отрасъла

Ценова промяна

Heron Therapeutics Inc Прогноза

Ценова цел

By TipRanks

208.06% нагоре

12-месечна прогноза

Среден 6.5 USD  208.06%

Висок 9 USD

Нисък 4 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Heron Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

2.2 / 2.425Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Weak Bullish Evidence

Настроение

By Acuity

122 / 386 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.